20
Participants
Start Date
December 31, 2013
Primary Completion Date
April 30, 2018
Study Completion Date
July 31, 2018
ganetespib
Phase 1 Dose 1: 150 mg/m² IV on days 1, 8, and 15 intravenously over 1 hour; Phase 1 Dose 2: 200 mg/m² IV on days 1, 8, and 15 intravenously over 1 hour; Phase 2: 200 mg/m² IV on days 1, 8, and 15 intravenously over 1 hour
Sirolimus
4mg taken orally once daily on a continuous dosing schedule; Loading dose 12 mg on cycle 1 day 1 only.
Children's National Medical Center, Washington D.C.
National Cancer Institute, Bethesda
University of Michigan, Ann Arbor
University of Iowa, Iowa City
Washington University, St Louis
Huntsman Cancer Institute, Salt Lake City
Sarcoma Oncology Center, Santa Monica
Synta Pharmaceuticals Corp.
INDUSTRY
United States Department of Defense
FED
Sarcoma Alliance for Research through Collaboration
OTHER